Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

(2010) Efstathios Kastritis et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

(2008) K. Anargyrou et al.   HAEMATOLOGICA

Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents

(2008) Jesús San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA

Novel anti-myeloma agents and angiogenesis

(2008) Konstantinos Anargyrou et al.   LEUKEMIA & LYMPHOMA

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH